When a stock falls 65% in twelve months, it is natural to question the long-term investment thesis of that stock.
The headline numbers at Cochlear Ltd (ASX: COH) leave a lot to be desired.
The April guidance downgrade was one of the worst in the company's history.
Surgeons are doing fewer implants. Referrals from the hearing aid channel have slowed. The Middle East conflict is disrupting sales in a key region.
Add it all up and the temptation to sell Cochlear shares is entirely understandable.
But it might also be one of the most expensive mistakes a long-term investor could make right now.
Image source: Getty Images
Why the selloff has overshot
The market has priced Cochlear shares as though the structural demand for cochlear implants has permanently declined.
The evidence does not support that conclusion. Cochlear holds approximately 50% global market share in cochlear implants.
The addressable market exceeds six million patients in developed markets alone, with current penetration of just 3%.
Furthermore, the company has, over four decades, invested into of research and development, and has built a product moat that no competitor has come close to replicating.
CEO Dig Howitt stated the following in his April ASX announcement.
He said:
The clinical need for cochlear implants continues to grow, particularly for the adult and seniors segment. Cochlear implants are also associated with a lower incidence of dementia, with dementia rates lower than in hearing aid users and comparable to those with normal hearing.
Surgeries are being delayed by hospital capacity constraints and cost of living pressures.
But importantly for investors, they are not being cancelled because cochlear implants no longer work. The market appears to be ignoring this distinction.
What history tells us about situations like this
The pattern of a high-quality business experiencing a temporary operational setback, being sold down aggressively, and then recovering strongly over the following two to three years is one of the most consistent in investing history.
ResMed was sold down aggressively in 2025 on fears that GLP-1 obesity drugs would destroy demand for CPAP devices.
Those who sold missed a sharp recovery when real-world data showed the fears were significantly overstated.
Cochlear has already recovered approximately 6% from its decade low of $90 to trade near $95.10 today.
What the brokers say
The broker community is divided on Cochlear shares, but the bulls carry price targets that imply extraordinary upside.
Jarden carries a price target of $169 on Cochlear shares, implying upside of approximately 78% from their current price.
Wilsons Advisory has a buy recommendation, describing the current valuation as a rare entry point into one of Australia's finest healthcare businesses.
The consensus analyst price target sits at approximately $232, implying upside of more than 130% for investors who can hold through the volatility.
Morgans cut its target to $107.17 and holds a cautious view on the near-term recovery timeline. But even Morgans' cautious target implies upside from current levels.
The three-year case
In three years, one of two things will have happened.
Either the demand headwinds proved permanent and the selloff was justified, in which case Cochlear shares will have continued to struggle.
Or, far more likely based on the evidence, the hospital capacity constraints and cost of living pressures eased, surgical volumes recovered, the adult and seniors segment resumed its historical growth rate of approximately 10% per annum.
Cochlear shareholders who held through the pain will have been rewarded handsomely in this case.
Demographics support the second scenario. The global population is ageing. Hearing loss incidence rises sharply after 65. Dementia prevention is becoming an increasing priority for healthcare systems globally.
All three of those trends point in the same direction for Cochlear's long-term demand trajectory, regardless of what happens in FY2026.
Foolish takeaway
Selling Cochlear shares right now might feel like the sensible thing to do.
The near-term outlook is uncertain. The guidance cut hurts and the recovery will take time.
But the investors who will look back with regret in three years are more likely to be the ones who sold at $95 than the ones who bought.
Quality businesses rarely go on sale. When they do, the crowd is usually on the wrong side of the trade.
